secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2026-08-10T20:22:45+00:00
Accession:  0001935979-26-000067
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven Q2 net loss narrows to $137.3M; advances Graves, epilepsy, oncology pipeline
--------------------------------------------------------------------------------

- Net loss $137.3M ($0.91/share) vs $198.1M ($1.94/share) in Q2 2025; non-GAAP loss $118.1M ($0.78/share).
- Cash, equivalents, marketable securities and restricted cash totaled ~$270.5M as of June 30, 2026.
- BHV-1300 Phase 3 in Graves' initiated; Phase 1b showed >80% mean reduction of pathogenic TSHR-IgG1 by week 12.
- Opakalim RISE3 topline expected 2H 2026; IGE study showed median time to second seizure 141 vs 47 days placebo.
- New clinical supply agreement with Regeneron to evaluate BHV-1530 ADC in combination with Libtayo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/0001935979-26-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/bhvn-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001935979-26-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer